This study was conducted to assess the impact of GPIIb/IIIa blockade with tirofiban on costs during the initial hospitalization and at 30 days among patients undergoing high-risk coronary angioplasty.
GPIIb/IIIa blockers are a new class of compounds that have been shown in clinical studies to prevent complications after high-risk angioplasty.
The RESTORE trial was a multinational, blinded placebo-controlled study of 2,197 patients randomized to tirofiban or placebo following coronary angioplasty.
This economic assessment was a prospective substudy of the RESTORE trial, and included 1,920 patients enrolled in the U.S. Costs were estimated for the U.S. cohort based on their utilization of healthcare resources and on costs measured directly in 820 U.S. patients at 30 sites.
There was a 36% difference in the rate of the composite event of death, myocardial infarction (MI) and revascularization at two days between tirofiban and placebo (8% vs. 12%, p=0.002).
This difference was attributed to a reduction in nonfatal MI, repeat angioplasty, coronary surgery and stent placement.
These clinical benefits followed a similar trend at 30 days, with a 16% reduction in the composite event (p=0.10).
In-hospital cost, including professional and study drug costs, was $12,145 ± 5,882 with placebo versus $12,230+5,527 with tirofiban (p=0.75).
The 30-day cost was $12,402 ± 6,147 with placebo versus $12,446 ± 5,814 with tirofiban (p=0.87). (...)
Mots-clés Pascal : Dilatation instrumentale, Artère coronaire, Tirofiban, Analyse coût, Economie santé, Chimiothérapie, Traitement, Efficacité traitement, Homme, Inhibiteur thromboagrégation, Traitement instrumental
Mots-clés Pascal anglais : Instrumental dilatation, Coronary artery, Tirofiban, Cost analysis, Health economy, Chemotherapy, Treatment, Treatment efficiency, Human, Antiplatelet agent, Instrumentation therapy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0514855
Code Inist : 002B02G. Création : 18/05/2000.